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ABSTRACT

It remains unknown whether bone grafting influences dural osteogenesis
following cranial reconstruction. The purpose of this study is to 1) develop a model to
study non-vascularized and vascularized calvarial grafts; and 2) compare effects of bone
graft vascularity on calvarial healing.
Thirty-six rats were divided into Control and Experimental (EXP) groups.
Parietal defects were left empty on one side. Contralateral defects in Control, EXP1, and
EXP2 were partially filled with native parietal bone (sham), non-vascularized, and
vascularized bone grafts, respectively. Healing parameters were measured from serial
micro-CT scans.
Greater bone production resulted in Control and EXP2 versus EXP1 at later
stages. Healing progressed through bone islands within Control and EXP2 versus
marginal healing in EXP 1.
An animal model has been established to study non-vascularized and vascularized
calvarial bone grafts. Non-vascularized bone grafts may inhibit dural osteogenesis.
Greater understanding of vascular mechanisms underlying calvarial healing may have
implications for cranial reconstruction.

Keywords: Calvarial defect, bone healing, bone graft, non-vascularized, vascularized.
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CHAPTER 1.0 - INTRODUCTION
Skull reconstruction may be indicated for patients with congenital and acquired
skull anomalies. Reconstruction o f the cranial vault is performed on paediatric patients
with craniosynostosis, or premature fusion of one or more cranial sutures. Residual
calvarial defects may persist and require further reconstruction. Skull defects may also
result from resection o f congenital tumors, for example, dermoid cysts. Acquired skull
defects may be caused by traumatic injuries, oncologic resection, and infection or
evacuation o f hematomas.1 Understanding o f skull healing, however, remains
incomplete. Skull reconstruction may leave full thickness defects to spontaneously heal
It is unknown why certain calvarial defects may close, while others persist or even
increase in size (Fig. 1.0).

FIG. 1.0. CT scans of a child’s skull following reconstruction at one day (left)
and one year (right) post-operatively. Several calvarial defects have
spontaneously healed, while others (circled) have increased in size in the parietal
region.
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Clinically, goals of skull reconstruction are to protect and provide space for the
growing brain. Reconstructive options for skull reconstruction include both autogenous
bone as well as alloplastic implants. Indications for autologous bone reconstruction
include history of recurrent infection, proximity for potential sinus communication, or
compromised overlying soft tissue.2 Autogenous reconstruction is the gold standard in
children due to osseointegration over time that follows growth of the cranial vault.1,3
Higher complication rates have resulted following paediatric skull reconstruction using
alloplastic materials.4
Cranial vault reconstruction for paediatric patients with craniosynostosis is
performed to restore normal skull contour, which will accommodate underlying brain
growth. Segments from the cranial vault are removed, reoriented, and replaced as nonvascularized bone grafts in a more anatomic three-dimensional shape. Surgeons are faced
with the challenge of making the cranial vault and fossae larger using a finite quantity of
bone. Calvarial defects are not completely filled due to limitations in available bone,
which leaves residual post-surgical full thickness defects. Healing of these calvarial
defects is poorly understood, which supports the inclusion of full thickness defects in our
study design.
Split thickness calvarial bone grafting is another technique commonly performed
for cranial defect reconstruction in patients once the diploic space has developed,
generally by three years of age.5 Once the parietal region reaches adequate thickness at
approximately nine years of age, the outer table may be harvested in situ.5 In younger
patients, full thickness bone is harvested and the calvarial tables are split ex vivo, which
2

minimizes donor site complications intra-operatively. If bone supply is adequate to fill
both the defect and donor site, the outer and inner tables are then inset as nonvascularized bone grafts in both sites. If an inadequate quantity of bone is available, the
donor site may be left to heal through dural osteogenesis, which refers to bone healing
driven by the dura.
The study of skull healing began through examination of prehistoric skulls with
trephination defects. Therapeutic indications for trephination were first outlined by
Hippocrates, including bone contusion, fracture, or contour deformity associated with
contusion or fracture.6 Historically, trephination had also been performed for
psychological benefit to release evil spirits from a diseased mind.7 Based on healing
patterns of trephination defects within ancient skulls, researchers have speculated on the
timing and cause of death.8 Defects with sharp margins and no evidence of bone healing
suggest that subjects did not survive the procedure or died shortly thereafter. In contrast,
other defects have shown smooth edges with varying degrees of bone healing following
trephination.8 The majority of trephination defects had been performed on adult subjects.
Osteogenic potential decreases with age, therefore even small calvarial defects in adults
may fail to heal spontaneously through dural osteogenesis.9
Osteogenic properties of the periosteum and dura in skull healing have been
confirmed.10'17 In the presence of calvarial bone grafts, it is currently unknown whether
healing progresses unchanged through dural osteogenesis or if healing mechanisms are
altered. Previous research has largely focused on the role of scaffolds and the
effectiveness of bone substitutes.18'33 The effects of non-vascularized versus vascularized
3

bone grafting on calvarial defect healing remain unknown. It is clinically relevant to
understand how the skull heals full thickness defects, both in adults and in children still
undergoing brain growth.
1.1 SKULL ANATOMY AND BLOOD SUPPLY

The rat skull consists of the cranium (also referred to as the neurocranium) and
facial bones (or splanchnocranium). The cranium includes the cranial base and cranial
vault. Paired frontal, parietal, and temporal bones, in addition to unpaired interparietal
and occipital bones, form the rat cranial vault.34 These bones articulate at cranial sutures,
which are formed of fibrous connective tissue.35 Each parietal bone forms a flat surface
and is bordered by the coronal suture anteriorly, sagittal suture in the midline, and
lambdoid suture posteriorly (Fig. 1.1).

\
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FIG. 1.1. Bird’s-eye view of the rat cranial vault (adapted figure). The parietal
bone on the left is highlighted in yellow. The coronal, sagittal, and lambdoid
sutures are shown in red, blue, and green, respectively.

In contrast to the blood supply o f long bones, a primary nutrient artery does not
supply the cranial vault.37 The blood supply originates from the middle meningeal artery,
in addition to arterioles perforating the inner table from the dura. Accessory blood supply
is also provided through foramina on the outer table by the pericranium, as well as
through insertions o f the temporalis muscles bilaterally. A large surface area of the
human cranial vault does not have muscle insertions, which results in a poorer blood
supply in comparison to other mammals.37
5

Cranial bones develop embryologically from membranes with a rich capillary
plexus. One or two nutrient arteries are initially present in the fetus, entering ossification
centers where bone is first produced.38 Vessel branches then radiate from these
ossification centers toward regions where cranial sutures later develop. In the mature
human skull, arterial and venous networks are present in cranial bones.38 Diploic
sinusoids are joined to pericranial and dural vessels by capillaries on the outer and inner
tables. Veins of Breschet are large sinuses in the diploe that are parallel to sutures and
also cross sutures (Fig. 1.2). They are united between the dura and pericranium. Greater
vessel density is seen surrounding cranial sutures. Vascular networks are also present in
the dura, including a primary plexus derived from meningeal vessels and an
anastomosing plexus from the external and internal carotid and vertebral arteries.38 The
relative importance of the dural versus pericranial vessels in supplying the cranial vault
remains undetermined.39

\
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FIG. 1.2. Classic venogram o f the rat cranial vault, showing Breschet veins and
trans-suture connections (adapted figure). Anterior and posterior references are
marked. Magnification x4.

1.2 BONE PHYSIOLOGY AND CLASSIFICATION
Bone is a form o f connective tissue, including an organic bone matrix that is
deposited by bone-producing cells called osteoblasts. Osteoblasts originate from stromal
cells o f mesenchymal origin and produce bone matrix and surround ingrowing
capillaries.40 Some osteoblasts differentiate into osteocytes when enclosed in bone
matrix, which are involved in maintenance and homeostasis of bone matrix and
mineralization.

7

Bone matrix becomes mineralized with calcium, phosphate, and carbonate.
Cancellous or spongy bone is formed by bone matrix deposition by osteoblasts in the
center of a bone. Compact bone is later formed on the outer and inner surfaces by
continuous deposition of bone sheets by osteoblasts. Osteoclasts are cells involved in
bone resorption and remodelling. They differentiate from a different cell lineage than
osteoblasts, most likely from mononuclear blood cells.40
Bone development may be classified according to its embryological origin as
either endochondral or intramembranous. Endochondral bone is formed through
ossification of a cartilaginous precursor. The skull base is formed by endochondral
ossification. Intramembranous bone, in contrast, does not have a cartilage intermediate
and forms by direct ossification of membranous sheets produced by mesenchymal cells.
Development of the cranial vault begins at multiple ossification centers through
intramembranous ossification. Some centers expand and coalesce to form cranial bones,
while others meet at fibrous junctions and become cranial sutures.41
Mature bone may be classified as cancellous (or spongy) versus cortical (or
compact). Cancellous bone consists of a network of interlacing fibres or trabeculae. It is
present in the shafts and ends of long bones, in addition to the majority of flat bones.40
Cortical bone is denser than cancellous bone and commonly found in the shafts of long
bones and surrounding bone cavities. The cranial vault is comprised of corticocancellous
bone. Layers of cortical bone encompass a central layer of cancellous bone or diploë.
Periosteum is present on both surfaces of the cranial vault, fusing with the dura on the
inner surface.2
8

Bone may also be classified based on the orientation of collagen fibres as woven
versus lamellar. Woven bone demonstrates random organization of collagen fibres and is
produced following a fracture prior to bone remodelling and during fetal development.
Lamellar bone is stronger and demonstrates parallel orientation of collagen fibres in
sheets.
Bone repair may be primary or secondary. Primary fracture healing occurs for
small bone defects or following rigid fixation of bone segments. It is analogous to
intramembranous ossification with direct formation of woven bone.2 In contrast,
secondary bone repair progresses similarly to endochondral ossification. Callus
formation occurs with a cartilaginous intermediate prior to bone deposition, for example,
as seen in fracture healing without rigid fixation.
Fracture healing occurs in three stages: inflammation, repair, and remodelling.42
In primary bone healing, minor or no hematoma formation occurs. Osteoblasts begin
producing bone at the margin between viable and necrotic bone. Osteoclasts resorb bone
matrix across the fracture site by forming cutting cones. New bone matrix is formed by
osteoblasts as woven bone behind the cutting cone. It is later replaced by lamellar bone
through remodelling. The periosteum is critical in primary bone repair by providing
osteoprogenitor cells and mesenchymal stem cells. Fibrous union may result if bone
healing is incomplete.
Secondary bone repair involves a greater degree of inflammation. Necrotic tissue
leads to chemotaxis of primitive mesenchymal cells, which develop into osteoblasts.
Vasodilation and hyperaemia are mediated by various cytokines, prostaglandins, and
9

histamines.43 Hematoma formation occurs, leading to organization of a fibrin network.
Neutrophils, basophils, and phagocytes infiltrate the region in order to clear necrotic
tissue. The inflammatory phase peaks within the first 48 hours post-injury and decreases
by one week in humans. The reparative phase begins within the first few days after
fracture, persisting for months. Callus consists of cartilage, small amounts of woven
bone, fibrous tissue, unmineralized bone matrix, and new blood vessels.43 Primary callus
matures into hard callus, which then becomes ossified. Callus formation continues for a
few weeks and then ceases to grow. If the fracture has not united, the callus may be
resorbed. Calcification of the callus occurs by direct bone mineral deposition by
osteoblasts. Collars of bone from the fracture margins advance towards each other until a
bridge is formed. The cellular components of a callus come from either periosteum or
bone marrow. Remodelling then predominates, as woven bone and/or calcified cartilage
is replaced with mature lamellar bone.44 Remodelling is influenced substantially by
mechanical forces experienced by the bone, a phenomenon described as Wolffs law.45
\
1.3 SKULL GROWTH

Growth of the cranial vault occurs in two ways: sutural and periosteal growth.46
Sutural growth leads to appositional bone formation at the cranial bone edges. Cranial
sutures are centers of cranial growth formed by three zones; a cellular layer bordering the
bone edge, a fibrous layer, in addition to a middle zone containing blood vessels that
connects the fibrous layers.47 The cellular layer contributes osteoprogenitor cells that
differentiate into osteoblasts, which create bone matrix. Sutural growth occurs
perpendicular to the orientation of the cranial suture. The sagittal and coronal sutures
10

therefore contribute to an increase in width and longitudinal growth, respectively, of the
neurocranium. Periosteal growth is bone remodelling that results from the differential
between osteoblastic and osteoclastic activity. Osteoblasts lead to bone production on the
outer surface of the calvarial bone. Within the rat parietal bone, osteoblasts deposit up to
470pm3 of bone matrix per day.48 Resorption simultaneously occurs via osteoclasts on
the inner bone surface, which leads to bone expansion towards the outer surface.
Periosteal growth increases bone formation on the convex outer surface and resorption on
the inner concave surface, which leads to proportionate growth. Growth of the cranial
vault is influenced by both genetic and epigenetic factors, however underlying brain
growth remains a dominant driving force.

1.4 BONE GRAFTS

Bone grafts may be classified based on the origin of the graft, anatomic
placement, composition, blood supply, and goal of augmentation.49 Bone grafts may be
harvested and transplanted into the same individual (autograft), a different individual of
the same species (allograft), or member of a different species (xenograft). They may be
grafted into the same (orthotopic) or different anatomic location (heterotopic).
Classification may also be based on bone graft composition, for example, cortical,
cancellous, corticocancellous, or osteochondral. The original blood supply may be
maintained to the bone graft (vascularized) or it may rely upon the recipient site for
revascularization (non-vascularized bone graft). In addition, bone grafts may be intended
to fill bone gaps (inlay) or augment bony projection (onlay grafts).

11

Bone regeneration from bone grafts results from osteoinduction, osteoconduction,
and osteogenic cells. Osteoinduction induces the recipient site to produce new bone by
recruiting mesenchymal cells to differentiate into osteoblasts. This process is driven by
bone graft-derived proteins, for example, bone morphogenetic proteins (BMPs).
Osteoconduction refers to supporting bone growth by providing three-dimensional
structure for ingrowth of blood vessels and osteoprogenitor cells.49 Incorporation of bone
grafts occurs by both osteoinduction and osteoconduction through creeping substitution,
meaning that the bone graft is ultimately replaced by host bone.
Healing of bone grafts occurs similarly to fracture repair. The inflammatory
phase predominates for the first five days in humans. Devitalized tissue is debrided by
polymorphonuclear cells prior to vascular ingrowth. Neovascularization varies
depending on vascularity of the recipient site, size, and type of graft. Necrotic bone is
then resorbed by osteoclasts. Bone grafting of endochondral bone results in a
cartilaginous soft callus produced by chondroblast differentiation. Hard callus formation
follows by calcification of the chondroid matrix. Membranous bone grafts lead to woven
bone deposition without a cartilaginous precursor. Remodelling results in lamellar bone
replacing woven bone.
Differences exist in incorporation of cortical versus cancellous bone grafts.2
Osteoclast activation and bone resorption initially predominate within cortical bone
grafts. Neovascularization begins approximately one week post-operatively, followed by
osteoblast activation and bone deposition. Complete revascularization may be delayed
until two months post-operatively. Remodelling may continue for two years, as woven
12

bone is replaced with lamellar bone. Osteoblast activation is the initiating factor in
healing of cancellous bone grafts. Osteoid deposition proceeds progressively. Vascular
ingrowth occurs rapidly in cancellous bone grafts, independent from osteoclast
resorption. It is usually completed by two weeks post-operatively in humans.
1.5 CALVARIAL DEFECT MODEL AND “CRITICAL SIZE DEFECT”

Bone healing has been extensively studied in animal models using both calvarial
defect and long bone models. Differences between these models however, prevent
findings from being generalized beyond the initial site of study. The cranial vault does
not have a primary nutrient artery. Embryological development also progresses through
intramembranous ossification in the cranial vault versus endochondral ossification in long
bones. Although embryologie development may influence future bone healing,
mechanical factors play a dominant role in bone healing. The cranial vault is not subject
to weight-bearing loads as in long bones.37
\
The rat model of calvarial defect healing commonly consists of a single central
defect, ranging from 411,50'52 to 9mm.25,53‘58 The central defect is created over the
sagittal sinus, whereby the dura is adherent to the overlying bone. Surgical risks
therefore include intra-operative hemorrhage and death. Connective tissue of the sagittal
suture is also included at the bone healing site.59 The bilateral defect model was
introduced to eliminate the sagittal suture and sinus from the surgical site. It involves
creation of full thickness calvarial defects in both parietal bones. Advantages of the
bilateral model include decreased risk of lacerating the sagittal sinus and dura,
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elimination of connective tissue of the suture from bone healing, and paired statistical
analysis. In the bilateral model, parietal bone dimensions limit the defect diameter
between 460"61 and 6mm24,62'66.
The “critical size defect” has been defined as the smallest size bone defect that
will not spontaneously heal over an animal’s lifespan.37 It remains a controversial
concept, since widely differing defect diameters have been reported as “critical size”
using the rat calvarial defect model. Diameters have ranged from 4,11 523,28, 59,67'71, a 62
gi6-i7,19, 21, 26, 72-83^tQ 9mm 25 study designs have varied with respect to animal age and
species, defect location and size, as well as presence or absence of overlying periosteum,
which are all factors known to influence calvarial defect healing.37
The requirement for defects of “critical size” has been emphasized in the
literature.59 Radiologic advances now permit serial imaging in vivo of the same animals,
which enable quantification of bone healing and comparison of healing rates over time.
The bilateral defect model may overcome the necessity for defects of “critical size”, since
each animal may provide a Defect and Treatment side for statistical comparisons.
Within previous studies, animal age at time of surgery has ranged from 4 weeks84
to 20 months85, which may significantly affect calvarial defect healing. Skeletally
immature rats have greater potential for bone healing, which may be a confounding
variable.13,37 In order to compare differences in bone healing within Defect versus
Treatment sides, adult models should optimally be used.
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Growth of the rat skeleton however, continues through adulthood. Although the
rate of growth decreases, the rat neurocranium continues to increase in both width and
length.86 Appositional growth from the periosteum leads to proportionate increase of the
neurocranium.47 Calvarial defects may similarly increase in size in proportion to overall
growth of the cranial vault, which has not been accounted for in previous studies.

1.6 CALVARIAL DEFECT RESEARCH
In vitro studies may lead to greater understanding of basic mechanisms of bone
production. The effects of different proteins and metabolites 23,87 on osteoblast
differentiation and osteoblast production of bone-forming proteins are well-known from
tissue culture studies. Techniques to measure osteoblast differentiation and maturation
include cellular proliferation assays, matrix metalloproteinase production, and mRNA
expression of osteoblast phenotypes.

Osteoblast activity may be quantified in vitro

using histochemical staining for expression of an early marker, alkaline phosphatase
(ALP).

Studies have also applied histochemical staining in addition to radiologic

imaging to measure mineralization over time.15,87
Animal models provide a less controlled method than in vitro studies for assessing
bone production and healing and may more closely represent human physiology.
Techniques may require animal sacrifice prior to study (ex vivo) or permit investigation in
living animals (in vivo). Histologic examination provides a qualitative assessment of
tissue specimens ex vivo. Using light microscopy and tissue staining, histologic
preparations permit visualization of fibrous connective tissue, blood vessels, and bone
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architecture, including osteoblasts and osteocytes. Ordinal grading scales have been
developed to assess calvarial defect healing based on histologic findings, ranging from
complete, partial, to no closure.88 Histomorphometry may also be applied ex vivo to
quantify bone production. Bone fractional area remains the most commonly used
measurement to study calvarial defect healing. It indicates the percentage of new bone
formation to the area of the original calvarial defect from a two-dimensional specimen.
Immunohistochemistry has also been used to study bone production in ex vivo studies, by
providing antibodies that bind specific antigens (for example, proteins produced during
bone production, such as osteocalcin).68 Radiologic imaging, including plain films and
micro-computed tomography, may also be applied ex vivo and evaluated using either
ordinal grading scales or quantitative methods.10,23,25,78,89'90
Radiologic evaluation in vivo may provide several advantages over ex vivo
techniques for studying bone production. Fewer animals may be required to achieve
adequate statistical power. Studying the same animals yields greater information about
bone healing over time. Radiologic examinations may be performed serially through
non-destructive techniques. In contrast, preparation of histologic specimens requires
décalcification, which may alter bone architecture.
Previous studies have used plain radiographs to image both excised cranial
specimens 63,72,74,76,91-93 as well as live animals over time.20,29,84,94 An x-ray beam
consists of relatively high energy photons directed towards an animal or specimen, which
may pass through or be absorbed by different anatomic structures.95 These photons
ultimately strike an x-ray film or digital detector and then create an image corresponding
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to the sum of different radiodensities.95 Plain films provide two-dimensional
representation of three-dimensional bony architecture. Measurements of bone healing
obtained from radiographs are therefore limited to surface area measurements, for
example, bone fractional area.12,81,96 Patterns of bone formation, either from defect
margins or as islands of bone formation,84,91,94 and qualitative evaluations for extent of
defect closure65 may also be determined.
Micro-computed tomography (micro-CT) is a radiologic modality that permits
non-destructive imaging of bony architecture in high resolution. An x-ray beam is
directed through an animal or specimen from different angles, which attenuates to
varying degrees when passing through anatomic structures of varying densities.

The

focal spot is significantly smaller for the x-ray beam in micro-CT versus plain films,
which accounts for increased resolution. As for plain films, the x-ray beam ultimately
reaches a two-dimensional detector. Three-dimensional reconstructions are then created
from hundreds of two-dimensional images that were acquired from different angles.
The majority of studies using micro-CT to image rat calvarial defects were performed on
ex vivo cranial specimens.18'19,24,98 Live animal micro-CT scanning has been developed
in recent years and also applied to the calvarial defect model.28"30,97,99"101 Quantitative
measurements of bone production from three-dimensional micro-CT scans include
volumetric analysis. Total bone mineral content may be determined within a volume of
interest and studied within the same animal over time.100 A micro-CT protocol has been
optimized at our local institution to study calvarial defect healing in vivo with high
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precision (±2.5%, Preclinical Imaging Research Centre, Robarts Research Institute,
London, ON).100
1.7 PURPOSE

The purpose of this study is to develop a model in which to study the effects of
non-vascularized versus vascularized bone grafting on calvarial defect healing.
Additional objectives are 1) to evaluate bone healing parameters within calvarial defects
while accounting for cranial vault growth; 2) to determine if correlation exists between
bone mineral content (BMC), bone mineral density (BMD), and bone fractional area
(BFA) within calvarial defects; 3) to determine if patterns of bone healing differ between
groups; 4) to determine if differences exist in mineralization of vascularized versus nonvascularized bone grafts over time; 5) to determine if differences exist in calvarial healing
based on bone graft position within the cranial vault; and 6) to compare findings obtained
from micro-CT scans undergoing rigid body registration based on two different sets of
landmarks (anteriorly vs. posteriorly-based).
\

1.8 NULL HYPOTHESES

We hypothesize that no differences will exist in healing of calvarial defects
partially filled with bone grafts, either vascularized versus non-vascularized, or no bone
graft. The null hypothesis may support a dominant role of dural osteogenesis in calvarial
healing, which may proceed independently and not be influenced by bone graft
vascularity.
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In addition, we hypothesize 1) that no significant differences will exist for bone
healing parameters obtained from micro-CT scans accounting for and not accounting for
skull growth; 2) that BMC, BMD, and BFA will correlate over time; 3) that patterns of
bone healing will not significantly differ between groups; 4) that no differences will exist
in mineralization of vascularized versus non-vascularized bone grafts; 5) that no
differences will exist in calvarial healing based on bone graft position within the cranial
vault; and 6) that findings will correlate when we compare data obtained from micro-CT
scans undergoing two different implementations of rigid body registration, based on
anteriorly- versus posteriorly-based landmarks.

\
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CHAPTER 2.0 - METHODS

2.1 EXPERIMENTAL DESIGN

Prior to study initiation, ethics approval was granted from the Council on Animal
Care at the University of Western Ontario (#2009-088, Appendix A). Thirty-six adult
male Wistar rats were randomly assigned to control (n=6) versus three experimental
groups (n=10 per group). Animals were 10 weeks of age and approximately 300g at time
of surgery. Acclimatization took place at the UWO Animal Care Facility for 72 hours
pre-operatively. Throughout the study, rats were housed under standard light-dark cycles
and given free access to commercial rat chow and water.
Study design was based on a bilateral model, therefore providing a Defect versus
Treatment (Sham or Bone Graft) side within each animal. It was not necessary for
defects to be of “critical size” since quantification of bone healing and comparisons
between sides and groups would be permitted. Surgical technique incorporated a handdriven tool to create calvarial defects as an alternative to powered instruments, therefore
minimizing the potential for thermal injury to bone.102 We chose the rat model because it
is less sentient than other animals for studying calvarial defect healing (e.g. dog,

7

rabbit,104' 106 pig107). Parietal bones of the rat include both cortical and cancellous bone
and dimensions are adequate to create bilateral defects of 4mm. Rats are readily
available, relatively easy to anesthetize and monitor intra- and post-operatively, and
resilient for serial imaging under anesthesia.59 Parietal defects are stable and not subject
to weight-bearing, which minimizes the risk of bone graft migration even without skeletal
fixation.59
20

Operative Technique
Surgeries were performed in accordance with the University of Western
Ontario Animal Use & Care Committee. General anesthetic was induced using
isoflurane 4% in a gas chamber and maintained at 2.5% via nose cone throughout
surgery. Glycopyrrolate (0.5 mg/kg) was administered intramuscularly to reduce
salivation and tracheobronchial secretions. Surgical sites were then shaved, prepped
using 10% povidone-iodine solution, and draped in sterile fashion.
Surgeries were performed under 2.5x loupe magnification. A 3cm midline
sagittal scalp incision was created, extending from the prefrontal to occipital region. Skin
flaps and subcutaneous tissue were retracted using retaining sutures to expose the
periosteum. An H-shaped incision was made in the periosteum overlying the coronal,
sagittal, and lambdoid sutures. Periosteal flaps were raised using a periosteal elevator
and reflected laterally, exposing the denuded parietal bones. Saline irrigation was
performed intermittently during surgery to avoid desiccation of bone or dura.
\
Full thickness calvarial defects were created using a hand-driven dermal biopsy
punch according to surgical group.
Control Group (n=6)
On the Defect side (right parietal bone), a 4mm calvarial defect was created with
an adjacent full thickness crescent defect. On the Treatment (Sham) side (left parietal),
only a single 4mm calvarial defect was created. Native parietal bone surrounding the
Sham defect was not disrupted (Fig. 2.0). Two 5’0 viciyl sutures were then secured
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anteriorly and posteriorly between the temporalis muscles across the parietal bones.
These sutures were intended to secure bone grafts in the Experimental groups and were
performed for standardization purposes in the Control group.

Anterior

Posterior
Parietal bones
FIG. 2.0. Control group (n=6)
The intra-operative photograph on the left shows a bird’s-eye view of the rat
skull. Anterior and posterior references are marked. Calvarial defects were
created in the parietal bones bilaterally, which are separated by the sagittal suture
seen in the midline. The dura and dural arterioles are visible at the base o f the full
thickness calvarial defects. The schematic diagram corresponds to the intra
operative photograph. (4mm, full thickness calvarial defect with 4mm diameter;
def, full thickness crescentic defect.)

Bilateral 4mm calvarial defects were also created in experimental groups #1-3
(n=10 per group) and bone grafting was performed according to surgical group (Fig. 2.1).
Procedures were limited to the parietal bones bilaterally, which were clearly delineated
by the coronal, sagittal, and lambdoid sutures. Care was taken to avoid including
connective tissue o f the sutures in all calvarial defects and bone grafts.
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Experimental Group #1 iE X P lt ('n=10'>

EXP1 received an adjacent full thickness crescent defect posterior to the 4mm
calvarial defect within the left parietal bone (Defect side). On the Treatment (Bone
Graft) side (right parietal region), non-vascularized bone grafting was performed. Nonvascularized bone grafts were completely incised along the margins and removed from
the cranial vault, therefore disrupting blood supply from dural arterioles. The crescent
shaped bone was then irrigated and returned to the harvest site as a non-vascularized bone
graft. Two 5’0 vicryl sutures were then secured between the temporalis muscles
anteriorly and posteriorly, which supported and anchored the bone grafts into position.
Experimental Group #2 1EXP21 fn=T0t
EXP2 also received a full thickness crescent defect adjacent to the 4mm calvarial
defect of the left parietal bone (Defect side). The Treatment (Bone Graft) side (right
parietal region) underwent vascularized bone grafting adjacent to the 4mm calvarial
defect. Vascularized bone grafts were completely incised along the margins until
ballotable using the tip of the scalpel blade. They were not however removed from the
cranial vault, therefore ensuring preservation of vascularity from underlying dural
arterioles. Vascularity was confirmed by inspection intra-operatively. Vascularized bone
grafts maintained a pink cast, appearing similar in color to native parietal bone. Two 5’0
vicryl sutures were then secured between the temporalis muscles, both anteriorly and
posteriorly, as in EXP1.
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Experimental Group #3 (EXP3) (n=T0)
On the Defect side (left parietal bone) in EXP3, full thickness crescents were
created both anteriorly and posteriorly to the 4mm calvarial defect. On the Treatment
(Bone Graft) side (right parietal region), both non-vascularized and vascularized bone
grafting was performed. In half o f the animals, vascularized bone grafts were performed
anteriorly, versus posteriorly in the other half. Two 5 ’0 vicryl sutures were then placed
between temporalis muscles bilaterally to support and anchor the bone grafts into position
(Fig. 2.2).

Defect

Treatment

EXP1

EXP2

EXP3

(n=10)

(n=10)

(n=10)

FIG. 2.1. Experimental groups #1-3 showing Defect and Treatment (Bone Graft)
sides within the left and right parietal bones, respectively. Anterior and posterior
references are marked.
(4mm, full thickness calvarial defect with 4mm diameter; def, full thickness
crescentic defect; BG = Bone Graft side; N-V = non-vascularized bone graft;
VAS = vascularized bone graft.)
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Fig. 2.2. Two 5 ’0 vicryl sutures were placed between the temporalis muscles
across the parietal bones, both anteriorly and posteriorly, in all surgical groups. In
EXP 1-3, these sutures were intended to anchor bone grafts and prevent migration.
In the Control group, vicryl sutures were also placed between the temporalis
muscles for standardization purposes.

Care was taken to avoid injury to the underlying dura and brain while creating
calvarial defects and harvesting bone grafts. Malleable retractors were fabricated using
sterile foil and positioned to prevent contact between the dermal biopsy punch and dura at
the crescent margin (Fig. 2.3). The retractor was not inserted deep to the parietal bone to
avoid disruption o f the dural arterioles supplying the calvarial bone.

25

FIG. 2.3. Malleable retractor used to prevent laceration to the dura during
creation o f crescent defect and bone graft harvest. Retractors were fabricated
using sterile foil and positioned at the crescent margin.

Within all groups, running 5’0 vicryl suture was used to reapproximate the
periosteal flaps followed by skin closure. Interrupted resorbable sutures were used to
reinforce the skin incision to minimize the risk o f dehiscence. An ear marking punch was
used to assign a unique identifier to each animal. Prior to reversal o f the general
anesthetic, marcaine 0.25% (8mg/kg) was infiltrated at the incision site to provide longacting local anesthesia.
Post-operative assessments were performed daily for the first week to monitor
pain control and incision healing. Pain control was assessed by observing each animal’s
general behaviour, feeding patterns, and frequency o f urination.
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2.2 IMAGING PROTOCOL

Serial micro-computed tomography (micro-CT) scans were performed
immediately post-operatively to provide baseline imaging of calvarial defects and bone
grafts, and additional scans at 2, 6, and 12 weeks following surgery. General anesthetic
was achieved using isoflurane and was used continuously during each scan via nose cone.
The SpeCZT live animal micro-CT scanner (GE Healthcare Biosciences, London, ON,
Canada) was used for all scans. Animals’ heads were positioned using CT fluoroscopy
prior to each scan. Five-minute high resolution scans were performed at x-ray tube
voltage of 90kV and tube current of 40mA. Nine-hundred views were obtained with an
increment angle of 0.4°. Each scan included a calibration phantom overlying the rat’s
skull, including water, air, and a cortical bone-mimicking epoxy (SB3, Gammex RMI,
Middleton, WI, USA).
2.3 IM AGING ANALYSIS

Micro-CT scans were reoriented and measured using MicroView software
(Version 2.1.2, GE Healthcare Biosciences, London, ON). Three-dimensional
reconstructions were first created and linearly rescaled according to the CT number for
air (-1000 Hounsfield Units) and water (0 HU). Scans were reoriented with the sagittal
plane along the Z-axis. Further reorientations were performed to align coronal and axial
planes with the X- and Y-axes, respectively.
To distinguish bone from background soft tissue, the auto threshold was
calculated from gray-level histograms based on regions of interest (ROIs) containing
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roughly equal volumes of bone and soft tissue. The mean auto threshold (1100 HU, SD
84) was then applied for analysis. Standardized ROIs of 10 pixels3 were created within
the cortical bone-mimicking epoxy and the mean signal density (2300 HU, SD 58) was
used for bone analysis of all micro-CT scans. Lower exclusion criteria for bone analysis
were set at the lower limit of soft tissue from gray-level histograms including equal
volumes of air and soft tissue. The mean (-300 HU, SD 41) was applied for analysis.
The lower exclusion criteria ensured that air was not included in bone analysis, which
would erroneously decrease bone mineral calculations.
ROIs were selected on micro-CT scans taken on post-operative day one (week 0)
using MicroView. Cylindrical ROIs of 4mm diameter and 2mm thickness were created
on the Defect and Treatment (Sham or Bone Graft) sides for each animal (Fig. 2.3.0).
The x, y, and z coordinates were recorded. Using the Advanced ROI Tools in
MicroView, crescentic ROIs were created using the Spline feature (Fig. 2.3.1). The
crescent was traced on a transparency sheet and then plotted at the most superior aspect
of the parietal bone. The contour was then extruded -2mm to create a 3-dimensional
crescentic ROI spanning the full thickness parietal defect.
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Fig. 2.3.0. Example o f cylindrical ROI created within a calvarial defect (bird’seye and oblique views).

Fig. 2.3.1. Example o f crescentic ROI created using Spline tool in MicroView.
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Micro-CT scans were co-registered in order to standardize the position of ROIs
over time. For each animal, scans at weeks 2, 6, and 12 were co-registered with the
micro-CT scan at week 0 through rigid body registration. Four corresponding landmarks,
identified from the cranial sutures anteriorly, were plotted on each scan (Fig. 2.3.2).
Landmarks included the junction between sagittal and coronal sutures, as well as
morphologic features identified along the sagittal suture anteriorly and coronal sutures.
The fusion view showed the superimposed micro-CT (week 2, 6, or 12) overlying the
week 0 scan. Co-registered scans were then saved and analyzed using ROIs at the same
coordinates that were identified in week 0 imaging.
Registrations were repeated for a subset of micro-CT scans at weeks 0 and 12 to
determine if differences exist based on selected landmarks for rigid body registration.
Scans of ten randomly selected rats were co-registered a second time using posterior
cranial suture landmarks (Fig. 2.3.3). Posterior landmarks included the junction between
sagittal and lambdoid sutures, as well as morphologic patterns identified along the sagittal
suture posteriorly and lambdoid sutures.
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FIG. 2.3.2. Anterior Suture Landmarks Plotted for Co-Registrations.
Three representative registrations showing anterior landmarks plotted on the week
0 (left) and week 12 (right) micro-CT axial slices.
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FIG. 2.3.3. Posterior Suture Landmarks Plotted for Co-Registrations.
Three representative micro-CT scans (axial slices) at weeks 0 (left) and 12 (right)
showing posterior landmarks. Scans were registered according to both anterior
and posterior suture landmarks to determine if differences exist based on anatomic
selections for rigid body registration.
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Further analysis was performed to account for skull growth over time. Although
cranial vault growth of rats slows over time, growth continues throughout adulthood.86
Standardized measurements of neurocranial length and width were recorded from the
imaging series. Maximum intensity projections (MIPs) along the Z-axis were created
from serial micro-CT scans of ten randomly selected rats at each time point.
Neurocranium length (y-dimension) was recorded between the anterior borders of the
foramen magnum and frontal bone. Width of the cranial vault (x-dimension) was
measured between the medial surfaces of the external auditory meati.

Average

increases in neurocranium length and width were then calculated at weeks 2,6, and 12.
ROIs for Defect and Treatment (Sham or Bone Graft) sides were then multiplied
by the average growth in neurocranium width (x) and length (y) over time. All ROIs
were maintained at 2mm thickness over time due to negligible increase in parietal bone
thickness over time.
2.4 STATISTICAL ANALYSIS

Sample size calculations were based on the formula shown in Figure 2.4, where zalpha equals 1.96 (alpha = 0.05, two-sided) and z-beta equals 0.84 (for power of 80%).108
Delta represents the difference that is considered clinically significant, which was
calculated between 10-20%. Previous studies on calvarial defect healing have applied
different measurement units, therefore calculations were based on standard deviations
reported for both bone fractional area and bone mineral content. Standard deviations of
bone fractional area for calvarial defect healing have ranged from 6.4% at 4 months
(4mm defects)60 to 16.3% at 6 weeks (6mm defects).62 The standard deviation for bone
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mineral content within 6mm defects has been reported as 15.1%.100 To detect a 10%
difference in calvarial defect healing between groups, a sample size of 7.2 to 18.3 animals
per group would be required. Sample size calculations ranged from 3.6 to 9.3 animals
per group to detect a 20% difference in calvarial defect healing. Given that housing,
imaging, and surgical expenses would be significant for 18 animals per group within this
pilot study, a conservative assignment of 6 animals for the control group and 10 per
experimental group was performed. These sample sizes are in keeping with the majority
of previous studies and strengthened since the bilateral defect model was employed.

n = 2 x {[(z-alpha + z-beta) x SD/delta] x 2}
FIG. 2.4. Formula for sample size calculations per group, where z-alpha equals
1.96 (alpha = 0.05, two-sided) and z-beta equals 0.84 (for power of 80%). SD
represents the standard deviation for calvarial defect healing reported in the
literature and delta is the difference considered clinically significant.

Statistical analysis was performed using SPSS software, version 17 (IBM,
Somers, NY, USA).
Within groups, bone mineral content and mineral density were compared between
Defect and Treatment (Sham or Bone Graft) sides at each time point using paired /-tests.
BMC analysis was performed based on ROIs held constant over time (4mm diameter)
that did not account for growth. It was then repeated based on ROIs that accounted for
average growth in both the x- and y-dimension over time.
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Differences in BMC between Treatment and Defect (T-D) sides were calculated
and compared between groups using one-way analysis of variance (ANOVA) at each
time point. If a difference was found using ANOVA, post-hoc comparisons were
performed using Tukey’s Honestly Significant Difference (HSD) t-test to identify the
difference between pairs. Multiple group comparisons were performed including the
Control, EXP1, and EXP2 groups, since these groups varied only with respect to one
variable on the Treatment side. The posterior crescent was either a sham (native parietal
bone without bone grafting), non-vascularized, or vascularized bone graft, respectively.
EXP3 was excluded from multiple group comparisons since greater surface area of bone
was removed on the Defect side.
Kruskal-Wallis and Wilcoxon two-sample tests were also applied for three- and
two-group comparisons, respectively. Non-parametric analysis was used to strengthen
the evidence associated with the small sample sizes.
Within EXP1 and EXP2, BMC of posterior crescents on Treatment (Bone Graft)
and Defect sides were compared using paired t-tests at each time point. Differences
between Treatment and Defect posterior crescents (T-D) were also compared between
groups over time using unpaired t-tests. Crescent volume was compared between groups
using ANOVA to test that no significant differences existed following creation of empty,
non-vascularized, and vascularized bone graft crescents.
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McNemar’s test was applied within groups to compare patterns of bone formation
between sides. Fisher’s exact test was used to compare bone healing patterns between
groups.
Pearson correlation coefficients were calculated using linear regression analysis to
determine if correlation exists between BMC and bone fractional area (BFA) within
groups over time.
EXP3 was subdivided into two groups (EXP3-ANT versus EXP3-POST) to
indicate the position (anterior versus posterior) of the vascularized bone graft on the
Treatment (Bone Graft) side. Anterior Bone Graft crescents were compared between
subgroups using independent samples ¿-tests. Posterior Bone Graft crescents were
similarly analyzed. In addition, vascularized bone grafts were compared between the two
subgroups, in addition to non-vascularized bone grafts. Lastly, anterior versus posterior
Bone Graft crescents were compared within subgroups using paired samples ¿-tests to
determine if any differences exist.
Fourteen randomly selected CT scans were measured on three different days to
calculate intra-rater reliability.109 Repeat measurements of BMC within cylindrical and
crescentic ROIs were compared using intra-class correlation coefficients (ICC).
Measurements from registrations based on anterior versus posterior landmarks
were also compared using the ICC to determine if correlation exists.
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CHAPTER 3.0 - RESULTS

Surgeries were performed on thirty-six Wistar male rats (6 controls, 10 per
Experimental group) that successfully completed all micro-CT scans over the 12 week
post-operative period. Two animals experienced traumatic injury to the underlying brain
intra-operatively and were euthanized. Six fatalities occurred intra-operatively at varying
stages of surgery; a few survived the entire procedure until skin closure while others died
prior to creation of any calvarial defects. Autopsies were performed by a veterinarian at
the UWO Animal Care Facility. Deaths were attributed to significant pulmonary edema
based on autopsy findings, however the etiology remains unknown. Viral respiratory
infections in rats are commonly asymptomatic, therefore underlying infection may have
contributed to anesthetic toxicity.110"111 Although isoflurane has a greater margin of
safety over many inhalational and injectable anesthetics, malfunction of the gas
anesthetic scavenger system may have contributed to pulmonary edema and subsequent
death.112 There were no further deaths once the gas anesthetic machine was replaced.
Intra-operative observations confirmed that perforating arterioles from the dura
maintained the blood supply to vascularized bone grafts. On gross examination,
vascularized bone grafts were pink in appearance whereas non-vascularized bone grafts
appeared white (Figure 3.0).
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FIG. 3.0. Intra-operative appearance o f non-vascularized and vascularized bone
grafts.
Gross inspection o f bone grafts intra-operatively demonstrated a pink cast to
vascularized bone grafts. Non-vascularized bone grafts, in contrast, appeared
white. VAS, vascularized bone graft; N-V, non-vascularized bone graft.

There were no post-operative complications. Additional analgesia was not
required following infiltration o f marcaine 0.25% prior to general anesthetic reversal. No
dehiscence or wound infections were noted. Micro-CT scans taken on post-operative day
one did not reveal any subdural or epidural collections or pneumocephalus.

3.1 BMC ANALYSIS NOT ACCOUNTING FOR GROWTH
Within Groups - Treatment versus Defect sides
Sample isosurface images o f rats within Control, EXP1, and EXP2 groups over
time are shown in Figures 3.1.0, 3.1.1, and 3.1.2, respectively.
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FIG. 3.1.0. Control rat at weeks 0, 2, 6, and 12 (from left to right).

BOAE!
GRAFT
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FIG. 3.1.1. EXP1 rat at weeks 0, 2, 6, and 12 (from left to right).
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FIG. 3.1.2. EXP2 rat at weeks 0, 2, 6, and 12 (from left to right).

In the Control group, no differences existed in BMC between Treatment (Sham)
and Defect sides at weeks 2 (¿>=0.460) and 6 (¿>=0.124, Fig. 3.1.3, Table 3.1.0). At week
12, higher BMC was seen on Sham versus Defect sides, which approached statistical
significance (¿>=0.072). No differences existed in BMC between Treatment (Bone Graft)
and Defect sides within EXP1 overtim e (Fig. 3.1.4, Table 3.1.0). Within EXP2, BMC
was greater on Treatment (Bone Graft) versus Defect side at week 12 (¿>=0.048, Fig.
3.1.5, Table 3.1.0). Similar trends were seen from non-parametric analysis, however the
difference between Bone Graft and Defect sides in EXP2 at week 12 did not reach
statistical significance (Table 3.1.1).
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FIG. 3.1.3. Bone mineral content o f Sham versus Defect sides for the Control
group not accounting for growth. BMC expressed in mg. Error bars represent
SEM.
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FIG. 3.1.4. Bone mineral content o f Bone Graft versus Defect sides for EXP1
group not accounting for growth. BMC expressed in mg. Error bars represent
SEM.
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FIG. 3.1.5. Bone mineral content o f Graft versus Defect sides for EXP2 group
not accounting for growth. BMC expressed in mg. Error bars represent SEM.
V =0.048.

Group

Week 2

Week 6

Week 12

Control

0.460

0.124

0.072

EXP1

0.452

0.192

0.315

EXP2

0.158

0.063

0.048*

Table 3.1.0. Paired t-tests comparing BMC o f Treatment (Sham or Bone Graft)
versus Defect sides within groups over time without accounting for skull growth.
Represents significance, p<0.05.
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Group

Week 2

Week 6

Week 12

Control

0.917

0.028*

0.028*

EXP1

0.285

0.285

0.241

EXP2

0.878

0.285

0.139

Table 3.1.1. Wilcoxon two-sample tests comparing BMC of Treatment (Sham or
Bone Graft) versus Defect sides within groups over time without accounting for
skull growth. Represents significance, p<0.05.

Between Groups - Treatment minus Defect (T-D) BMC Differences
BMC differences for Treatment (Sham or Bone Graft) minus Defect (T-D) sides
within all groups over time are shown in Figure 3.1.6. T-D differences were greater for
Control and EXP2 groups, which approached significance at weeks 6 (¿=0.060) and 12
(p=0.057, Table 3.1.2). Differences were not significant between groups at weeks 0
(¿=0.515) and 2 (¿=0.426).
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FIG. 3.1.6. Differences in BMC for Treatment minus Defect (T-D) sides within
groups over time without accounting for growth. BMC differences expressed in
mg. Error bars represent SEM.

Week

ANOVA

Kruskal-Wallis

0

¿>=0.515

0.869

2

0.426

0.414

6

0.060

0.117

12

0.057

0.082

Table 3.1.2. Statistical comparisons of BMC differences for Treatment minus
Defect (T-D) sides between groups without accounting for growth.
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3.2 S K U L L G R O W T H

Cranial vault growth was greater in length versus width. At week 2, the average
increase in skull width was 4.4% compared to an increase of 5.5% in length. Skull width
and length increased by 6.2% and 7.6% at week 6. Growth continued until study
completion at 12 weeks post-operatively, at which point skull width was 7.5% greater
with an accompanied 9.1% increase in skull length.
In order to confirm calvarial defect expansion in proportion to skull growth, MIPs
were reviewed at 12 weeks post-operatively. When clear distinction was possible
between native parietal and new bone formation, measurements were recorded for both
the x- and y-dimension (Fig. 3.2.0). Results from 6 MIPs confirmed that defect size
increased in size proportionate to overall skull growth in width and length. Average
calvarial defect dimensions at 12 weeks were 4.26 (x-) and 4.32 (y-dimension) mm
(Table 3.2.0).
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FIG. 3.2.0. Sample MIP o f rat skull showing expansion o f calvarial defect at 12
weeks. The junction between native parietal bone and new bone formation is
clearly demarcated. Calvarial defect length (y-dimension) in this example is
4.32mm at 12 weeks post-operatively. The calvarial defect has therefore
increased in size over the original defect, which was created 4mm in diameter.

47

Rat

x-dimension
(width, in mm)

y-dimension
(length, in mm)

7

4.41

4.32

22

4.24

4.28

26

4.27

4.42

35

4.31

4.35

38

4.17

4.24

39

4.17

4.32

Table 3.2.0. Defect side dimensions measured at 12 weeks from MIPs showing
clear demarcation between native parietal bone and new bone formation. As skull
growth continued through 12 weeks post-operatively, calvarial defects similarly
increased in size. Measurements expressed in millimetres.

Standard ROI dimensions were multiplied by the average increase in skull width
and length over time. Modified ROI dimensions accounting for skull growth are shown
in Table 3.2.1.
Week

x-dimension
(width, in mm)

y-dimension
(length, in mm)

0

4.00

4.00

2

4.18

4.22

6

4.25

4.30

12

4.30

4.36

Table 3.2.1. Modified ROI dimensions over time, accounting for rate of skull
growth in both width and length. Dimensions expressed in millimetres.
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3.3 B M C A N A L Y S IS A C C O U N T IN G F O R G R O W T H

Within Groups - Treatment versus Defect sides
Using modified ROIs to account for skull growth, findings for BMC
measurements were similar when comparing Treatment versus Defect sides within groups
over time. BMC data accounting for skull growth within groups at all time points are
included in Appendix B (Tables 3.3.0-3.3.3).
The Control group demonstrated greater BMC on the Treatment (Sham) versus
Defect side at week 12 (p=0.042, Fig. 3.3.0, Tables 3.3.4 and 3.3.5). No differences
existed in BMC on Sham versus Defect sides within the Control group at other time
points.
In EXP1 group, BMC between sides was not statistically different over time (Fig.
3.3.1, Tables 3.3.4 and 3.3.5). Greater BMC was seen within the EXP2 group on the
Treatment (Bone Graft) versus Defect side at weeks 6 (p=0.032) and 12 (p=0.024, Fig.
3.3.2, Tables 3.3.4 and 3.3.5).
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FIG. 3.3.0. Bone mineral content o f Treatment (Sham) versus Defect sides for the
Control group while accounting for growth. BMC expressed in mg. Error bars
represent SEM. *p=0.042.
\
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B M C (m g)

Defect Side
Graft Side

2

6

12

Time (weeks)
FIG. 3.3.1. Bone mineral content o f Treatment (Bone Graft) versus Defect sides
for EXP 1 group while accounting for growth. BMC expressed in mg. Error bars
represent SEM.
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B M C (m g)

■ Defect Side
■ Graft Side

Time (weeks)
FIG. 3.3.2. Bone mineral content o f Treatment (Bone Graft) versus Defect sides
for EXP2 group while accounting for growth. BMC expressed in mg. Error bars
represent SEM. *p=0.032; **p=0.024.

Group

Week 2

Week 6

Week 12

Control

0.550

0.091

0.042*

EXP1

0.597

0.193

0.427

EXP2

0.079

0.032*

0.024*

Table 3.3.4. Paired /-tests comparing BMC o f Treatment (Sham or Bone Graft)
versus Defect sides within groups over time while accounting for skull growth.
Represents significance, p<0.05.
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Group

Week 2

Week 6

Week 12

Control

0.917

0.028*

0.028*

EXP1

0.508

0.169

0.333

EXP2

0.074

0.028*

0.037*

Table 3.3.5. Wilcoxon two-sample tests comparing BMC of Treatment (Sham or
Bone Graft) versus Defect sides within groups over time while accounting for
skull growth. *represents significance, p<0.05.

Between Groups —Treatment minus Defect Differences
Differences in BMC between Treatment (Sham or Bone Graft) and Defect (T-D)
sides for all groups over time are shown in Figure 3.3.3. T-D differences were significant
between Control, EXP1, and EXP2 groups at weeks 6 (p=0.016) and 12 (p=0.025, Tables
3.3.6). At week 6, the T-D difference was greater for the Control vs. EXP1 group
(p=0.043, Table 3.3.7). The T-D difference was also greater for EXP2 vs, EXP1 group
(p=0.030). No differences were seen between the Control and EXP2 groups (p=0.978) at
week 6.
At week 12, T-D differences were greater for Control and EXP2 vs. EXP1 groups
(p=0.038 and 0.050, respectively). The Control and EXP2 groups did not show any
differences (p=0.817).
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■ EXP2

6

2

12
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FIG. 3.3.3. BMC differences for Treatment minus Defect (T-D) sides within
groups over time while accounting for growth. BMC expressed in mg. Error bars
represent SEM. */?=0.016; **/?=0.025.

Week

ANOVA

Kruskal-Wallis

0

p=0.515

0.869

2

0.278

0.140

6

0.016*

0.046*

12

0.025*

0.077

Table 3.3.6. Statistical comparisons o f BMC differences for Treatment minus
Defect (T-D) sides between groups while accounting for growth. *represents
significance, p<0.05.
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Group Comparisons

Week 6

Week 12

Control vs. EXP1

0.043*

0.038*

Control vs. EXP 2

0.978

0.817

EXP1 vs. EXP2

0.030*

0.050*

Table 3.3.7. Post-hoc Tukey’s Honestly Significant Difference (HSD) test to
identify differences between two-group comparisons following one-way
ANOVA. *represents significance, p<0.05.

BMC was underestimated when not accounting for growth. Ratios of BMC
measurements based on ROIs that accounted for growth versus those which did not are
listed in Table 3.3.8. During early stages of bone healing at week 2, BMC was
underestimated between 19.6-25.4%. At week 6, BMC was underestimated between
19.2-26.5% and 17.5-30.2% at week 12.

Control
EXP1
EXP2
EXP3

Treatment Side
Week 2 Week 6 Week 12
1.24
1.237
1.228
1.265
1.268
1.251
1.199
1.175
1.211
1.302
1.263
1.216

Week 2
1.254
1.219
1.202
1.196

Defect Side
Week 5 Week 12
1.245
1.209
1.248
1.233
1.192
1.191
1.264
1.233

Table 3.3.8. Ratios of BMC measurements Accounting for Growth to those Not
Accounting for Growth for Treatment and Defect sides within each group over
time.
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3.4 BMD ANALYSIS ACCOUNTING FOR GROWTH
Analysis for bone mineral density (BMD) supported BMC findings. Within the
Control group, greater BMD was seen on Treatment (Sham) versus Defect sides at week
12 ( p - 0.041, Fig. 3.4.0, Tables 3.4.0 and 3.4.1). BMD between sides was not statistically
different at week 2 (/?=0.583), however approached significance at week 6 (p=0.093).

No differences in BMD were seen for Treatment (Bone Graft) versus Defect sides
in EXP1 over time (Fig. 3.4.1). Within EXP2, BMD was higher on Treatment (Bone
Graft) versus Defect sides at weeks 6 (p=0.026) and 12 (p=0.024. Fig. 3.4.2, Tables 3.4.0
and 3.4.1).
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■ Defect Side
■ Sham Side
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FIG. 3.4.0. Bone mineral density on Treatment (Sham) versus Defect sides for
the Control group while accounting for growth. BMD expressed in mg/cc. Error
bars represent SEM. */?=0.041.
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BM D (m g/cc)

FIG. 3.4.1. Bone mineral density on Treatment (Bone Graft) versus Defect sides
for EXP1 group while accounting for growth. BMD expressed in mg/cc. Error
bars represent SEM.
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BMD (m g /cc)
FIG. 3.4.2. Bone mineral density on Treatment (Bone Graft) versus Defect sides
for the EXP2 group while accounting for growth. BMD expressed in mg/cc.
Error bars represent SEM. *p=0.026; **p=0.024.

Group

Week 2

Week 6

Week 12

Control

0.583

0.093

0.041*

EXP1

0.576

0.321

0.540

EXP2

0.067

0.026*

0.024*

Table 3.4.0. Paired t-tests comparing BMD o f Treatment (Sham or Bone Graft)
versus Defect sides within groups over time while accounting for skull growth.
Represents significance, p<0.05.

58

Group

Week 2

Week 6

Week 12

Control

0.917

0.028*

0.028*

EXP1

0.386

0.386

0.646

EXP2

0.074

0.028*

0.047*

Table 3.4.1. Wilcoxon two-sample tests comparing BMD of Treatment (Sham or
Bone Graft) versus Defect sides within groups over time while accounting for
skull growth. *represents significance, p<0.05.

3.5 CORRELATION BETWEEN BMC AND BFA

Correlation was seen between BMC and BFA measurements of Defect and
Treatment sides within groups over time. Within the Control group, BMC and BFA
correlated strongly on both Defect (r2=0.946, /K0.001) and Treatment (Sham) sides
(r2=0.939, p=0.024). Similar results for BMC and BFA correlation were seen within
EXP1, EXP2, and EXP3 groups for Defect (r2>0.888, p<0.003) and Treatment (Bone
Graft) sides (r2>0.824, /?<0.011).

3.6 PATTERNS OF BONE FORMATION

Patterns of bone formation were recorded from MIPs within groups over time and
confirmed using isosurface images. Bone formed within calvarial defects either as
islands of new bone formation or from defect margins. Bone healing patterns within
groups for Defect and Treatment (Sham or Bone Graft) sides are included in Figures
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3.6.0 and 3.6.1, respectively. In the Control group, healing progressed through islands of
bone formation within 50% of Defect sides and the majority (83.3%) of Sham sides. A
greater percentage of Defect sides (70%) in EXP1 group healed through islands of new
bone. Treatment (Bone Graft) sides however, in EXP1 healed primarily from bone
margins (70%). In EXP2, bone healing occurred through islands of bone formation
within the majority of Defect (70%) and Treatment (80%) sides.
Within groups, comparisons of bone healing patterns were not statistically
different between sides (control group,/?=0.500; EXPl,p=0.289; EXP2,/?= 1.000).
Across group comparisons did not show differences in patterns of bone formation on the
Defect side (p=0.758). Bone healing patterns on the Treatment (Sham or Bone Graft)
side however, were different between Control, EXP1, and EXP2 groups (p=0.047). In
the Control and EXP2 groups, healing occurred mostly as islands of new bone formation
when framed by vascularized bone (Fig. 3.6.2 and 3.6.3, respectively). In contrast,
Treatment sides partially filled with non-vascularized bone grafts in EXP 1 healed mostly
from defect margins (Fig. 3.6.4).
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80

■ Islands
■ Margins

Control

EXP1

EXP2

Group

FIG. 3.6.0. Patterns o f Bone Formation on the Defect side by Group

90

■ Islands
■ Margins

Control

EXP1

EXP2

Group

FIG. 3.6.1. Patterns o f Bone Formation on the Treatment (Sham or Bone Graft)
side by Group. Difference between groups in healing patterns on the Treatment
side was shown using ANOVA, *p=0.047.
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FIG. 3.6.2. Representative isosurface image for a Control rat at week 12, showing
healing through new bone islands on the Sham (animal’s left) side.

FIG. 3.6.3. Representative isosurface image for an EXP2 rat at week 12, showing
healing primarily through islands o f new bone formation on the Bone Graft
(animal’s right) side.
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FIG. 3.6.4. Representative isosurface image for an EXP1 rat at week 12, showing
marginal healing on the Bone Graft (animal’s right) side.

3.7 BMC ANALYSIS OF BONE GRAFTS VERSUS EMPTY CRESCENTS
Within Groups over time
BMC o f posterior crescents on the Treatment (Bone Graft) side increased over
time within both EXP1 and EXP2 (Fig. 3.7.0). For EXP1, differences were seen in BMC
when comparing all time points (p<0.001). BMC increased from week 0 to week 2
(p=0.018). BMC also increased significantly from week 2 to 6 (p<0.001) and from week
6 to 12 (/?=().()() 1). Posterior crescents on the Treatment side similarly increased in BMC
within EXP2 over time (p<0.001). BMC increased between weeks 0 and 2 (p<0.001), 2
and 6 (p<0.001), and 6 and 12 (p=0.001).
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■ EXP1
■ EXP2

Time (weeks)

FIG. 3.7.0. BMC o f posterior crescents on the Treatment (Bone Graft) side
within EXP1 and EXP2 over time. Error bars represent SEM. BMC expressed in
mg. */?=0.025.

BMC was greater within posterior crescents on the Treatment (Bone Graft) versus
Defect side within EXP1 at all time points (p<0.001, weeks 0-12). Similar findings were
seen when comparing BMC o f posterior crescents on the Treatment versus Defect side
within EXP2 (p<0.001, weeks 0-12).

Differences between groups fo r Posterior Crescents on Treatment minus Defect sides
over time
BMC differences for Treatment minus Defect (T-D) posterior crescents for EXP1
and EXP2 over time are shown in Figure 3.7.1. T-D posterior crescent differences
between EXP1 and EXP2 approached significance at week 0 (/?=0.072) and were greater
within EXP2 at week 2 (p=0.050, Table 3.7.0). Differences for T-D posterior crescents
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were no longer significant between EXP1 and EXP2 at weeks 6 (jp=0.423) or 12
(p=0.467).

FIG. 3.7.1. BMC differences in posterior crescents on Treatment (Bone Graft)
minus Defect (T-D) sides for EXP1 and EXP2 groups over time. BMC
differences expressed in mg. Error bars represent SEM. *p=0.050.

Comparison

WeekO

Week 2

Week 6

Week 12

/-test

0.072

0.050*

0.423

0.467

Wilcoxon

0.052

0.063

0.529

0.529

Table 3.7.0. Comparisons o f BMC differences in posterior crescents on
Treatment minus Defect (T-D) sides between EXP1 and EXP2 over time, /-test,
unpaired /-tests. Wilcoxon, Wilcoxon two-sample tests. Represents significance,
p<0.05.
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BMC differences between groups over time fo r Posterior Crescents on the Treatment Side
No differences in ROI volume were seen between groups for empty, nonvascularized, and vascularized crescents.
At week 2, BMC was higher for posterior crescents in EXP2 versus EXP1 on the
Treatment (Bone Graft) side (p=0.025, Figure 3.7.0, Table 3.7.1). No differences in
BMC were seen between EXP1 and EXP2 for posterior crescents at weeks 0, 6, or 12
(p=0.211, 0.586, and 0.747, respectively).
Findings were similar when accounting for skull growth. BMC of posterior
crescents on the Treatment (Bone Graft) side was higher in EXP2 versus EXP1 at week 2
(p=0.007, Table 3.7.2). Differences were not significant between groups at other time
points (week 0,p=0.117; week 6,/?=0.386; week 12,/?=0.645).

Comparison

WeekO

Week 2

Week 6

Weekv12

/-test

0.117

0.025*

0.383

0.741

Wilcoxon

0.203

0.080

0.722

0.872

Table 3.7.1. Statistical comparisons for posterior crescents on the Treatment side
between EXP1 and EXP2 over time not accounting for skull growth, /-test,
unpaired /-tests. Wilcoxon, Wilcoxon two-sample tests. Represents significance,
p<0.05.
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Comparison

WeekO

Week 2

Week 6

Week 12

t-test

0.117

0.007*

0.386

0.645

Wilcoxon

0.123

0.009*

0.529

0.796

Table 3.7.2. Statistical comparisons for posterior crescents on the Treatment side
between EXP1 and EXP2 over time accounting for skull growth. /-test, unpaired
/-tests. Wilcoxon, Wilcoxon two-sample tests. *represents significance, p<0.05.

3.8 BONE GRAFT POSITION IN CRANIAL VAULT, ANTERIOR VERSUS
POSTERIOR

No differences were noted in BMC over time between non-vascularized bone
grafts created anteriorly versus posteriorly in the parietal bone (Table 3.8.0).
Differences in BMC did not exist for vascularized bone grafts created anteriorly
versus posteriorly at weeks 0 (p=0.141) and 2 (p=0.285, Tables 3.8.0 and 3-8.1).
Vascularized bone grafts created posteriorly in the parietal bone demonstrated greater
BMC at weeks 6 (p=0.087) and 12 (p=0.029) versus those created anteriorly.
Week 2 Week 6 Week 12

Bone Grafts

WeekO

Non-vascularized

/?=0.827

0.271

0.106

0.224

Vascularized

0.141

0.285

0.087

0.029*

Table 3.8.0. Unpaired /-tests comparing BMC of Vascularized and NonVascularized bone grafts between EXP3-ANT and EXP3-POST. *represents
significance, p<0.05.
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Week 2 Week 6 Week 12

Bone Grafts

WeekO

Non-vascularized

p=0.917

0.347

0.076

0.251

Vascularized

0.117

0.465

0.117

0.028*

Table 3.8.1. Wilcoxon two-sample tests comparing BMC of Vascularized and
Non-Vascularized bone grafts between EXP3-ANT and EXP3-POST. *represents
significance, p<0.05.

Crescents on the Treatment (Bone Graft) side were compared between EXP3ANT and EXP3-POST. At weeks 0 and 2, no differences were seen when comparing
anterior and posterior crescents between subgroups (Tables 3.8.2 and 3.8.3). At weeks 6
and 12, no differences were seen in BMC for anterior crescents between subgroups
(p=0.516, week 6; ¿7=0.699, week 12). Posterior crescents showed greater BMC within
EXP3-POST versus EXP3-ANT at weeks 6 (¿>=0.055) and 12 (¿>=0.051).
Week 2 Week 6 Week 12

Comparison

Week 0

Anterior Crescents on
Treatment Side

/>=0.832

0.332

0.516

0.699

Posterior Crescents on
Treatment Side

0.178

0.250

0.055

0.051

Table 3.8.2. Unpaired ¿-tests comparing BMC of Anterior Crescents and
Posterior Crescents on the Treatment (Bone Graft) side between EXP3-ANT and
EXP3-POST.
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Week 2 Week 6 Week 12

Comparison

Week 0

Anterior Crescents on
Treatment Side

p=0.465

0.347

0.754

0.754

Posterior Crescents on
Treatment Side

0.175

0.251

0.047*

0.047*

Table 3.8.3. Wilcoxon two-sample tests comparing BMC of Anterior Crescents
and Posterior Crescents on the Treatment (Bone Graft) side between EXP3-ANT
and EXP3-POST. “represents significance, p<0.05.

For EXP3-ANT, no differences were seen when comparing anterior versus
posterior crescents on the Treatment side at each time point (Tables 3.8.4 and 3.8.5).
EXP3-POST demonstrated greater BMC for posterior versus anterior Treatment crescents
at weeks 2,6, and 12 (p=0.042, 0.012, and 0.010, respectively).
Week 2 Week 6 Week 12

Comparison

WeekO

EXP3-ANT

/>=0.767

0.950

0.573

0.342

EXP3-POST

0.070

0.042*

0.012*

0.010*
\

Table 3.8.4. r-tests comparing Anterior and Posterior Crescents on the Treatment
side within EXP3-ANT and EXP3-POST. ““represents significance, p<0.05.
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Week 2 Week 6 Week 12

Comparison

WeekO

EXP3-ANT

p=0.686

0.893

0.500

0.345

EXP3-POST

0.043*

0.043*

0.043*

0.043*

Table 3.8.5. Wilcoxon two-sample tests comparing Anterior and Posterior
Crescents on the Treatment side within EXP3-ANT and EXP3-POST.
♦represents significance, p<0.05.

On the Defect side, no differences in BMC over time were seen for anterior versus
posterior crescents at weeks 0 (p=0.518) and 2 (p=0.077). At weeks 6 and 12, posterior
crescents on the Defect side demonstrated greater BMC than anterior crescents (p=0.002
and 0.001, respectively).
3.9 CORRELATION BETWEEN DIFFERENT RIGID BODY REGISTRATIONS

Accuracy of plotting suture landmarks over time was estimated by recording rootmean-square (RMS) deviations from co-registrations (Table 3.9.0).
\
Co-registrations

Anterior Landmarks

Posterior Landmarks

Weeks 0 and 2

0.250 (0.096)

0.243 (0.106)

Weeks 0 and 6

0.417(0.170)

0.309 (0.173)

Weeks 0 and 12

0.467 (0.133)

0.437 (0.158)

Table 3.9.0. Root-mean-square (RMS) deviations of co-registrations based on
anterior and posterior suture landmarks. Standard deviations are shown in
brackets. Measurements expressed in mm.
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Measurements recorded from micro-CT scans that had been co-registered
according to anterior landmarks correlated strongly with those based on posterior
landmarks. Intra-class correlation coefficients for cylindrical ROIs measured from
anteriorly vs. posteriorly-based registrations were 0.917 and 0.924 on the Defect and
Treatment sides, respectively. Crescentic ROIs measured from the two registrations
demonstrated an ICC of 0.880 for empty defects and 0.894 for bone grafts.

3.10 INTRA-RATER RELIABILITY

Intra-rater reliability for measuring cylindrical ROIs demonstrated an intra-class
correlation coefficient (ICC) of 0.928. The ICC for repeat measurements of crescentic
ROIs was 0.883 for those left empty and 0.869 for those which were bone grafted.
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CHAPTER 4.0 - DISCUSSION

4.1 CALVARIAL HEALING AND ROLE OF BONE GRAFT VASCULARITY

Previous research on calvarial defect healing has largely focused on the
effectiveness of scaffolds and bone substitutes.21'22,26-33 Additional studies have
evaluated the osteogenic potential of local factors within bone graft recipient sites,
including the dura, periosteum, and adjacent bone. Using membranes to isolate the dura
and/or periosteum from bone graft healing, researchers have found that the dura may be
the most significant factor promoting revascularization and bone healing.13,113 When
bone grafts healed in isolation from both the dura and periosteum, the osteogenic and
angiogenic potential of adjacent bone was limited.13 The dura is theorized to be actively
osteogenic as well as by promoting adjacent calvarial marrow to form bone through
production of growth factors.13,113 Recipient sites in these studies contained nonvascularized bone grafts, which provided an acellular scaffold for bone healing.13,113
Cranial vault surgeiy often creates non-vascularized bone segments during
reconstruction, which may leave full thickness defects to spontaneously heal. It remains
unknown whether bone graft vascularity alters basic mechanisms of dural osteogenesis.
Irradiation of bone containing a central calvarial defect has been associated with impaired
healing, however the effects of bone graft vascularity on calvarial healing are poorly
understood.114
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Within all surgical groups, the dura was intact at the calvarial defect base and
periosteum reapproximated. Control, EXP1, and EXP2 groups differed only with respect
to the adjacent crescent on the Treatment (Sham or Bone Graft) side. In the Control
group, the adjacent crescent demonstrated the most robust blood supply within this study.
It was supplied by the arterial network within the parietal bone, in addition to perforating
arterioles from the dura. The pericranial vessels were disrupted however during exposure
of the parietal bones. Blood supply of the adjacent crescent on the Treatment (Bone
Graft) side in EXP2 was less than that of the Control group. Vascularized bone grafts
were supplied only by dural arterioles. The adjacent crescent on the Treatment (Bone
Graft) side within EXP1 was completely non-vascularized, since the arterial plexus
within the parietal bone, dural, and pericranial vessels were all disrupted.
Findings suggest that bone graft vascularity significantly affects the quantity of
bone produced during calvarial healing. At weeks 6 and 12, healing was impaired on the
Treatment side within rats undergoing non-vascularized bone grafts as compared to
vascularized grafts or shams. Calvarial healing was not statistically different in the
presence of native parietal bone versus vascularized bone grafts on the Treatment side.
Non-vascularized bone grafts may initiate greater osteoclastic activity, which may
decrease overall bone production during calvarial healing. An alternative theory is that
dural osteogenesis may be inhibited by local release of intracellular contents following
osteocyte death in non-vascularized bone grafts. Revascularization of non-vascularized
bone grafts may not be complete, which may make delivery of dural growth factors less
efficient as well as result in fewer endothelial cells to stimulate.
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Previous research has shown osteogenic properties to be lower for the periosteum
than for the dura.13,113 The periosteum may in fact inhibit calvarial defect healing if
significant soft tissue prolapse occurs, which mechanically obstructs bone formation.115'
117 Similarly, bone formation was enhanced within parietal defects that were propped
open using two membranes.88 Since calvarial defects were smaller (4mm) within this
study, there was lower risk of periosteal prolapse. Bone graft vascularity appeared to
have a synergistic effect with the periosteum and dura in promoting calvarial defect
healing.
The majority of previous studies employed powered instruments to create
calvarial defects. Thermal injury to bone may result even when accompanied by saline
irrigation, which may irreversibly damage blood vessels in adjacent bone.118 Greater heat
is generated with increasing drill diameter, therefore the extent of thermal injury to
calvarial bone may have varied between studies.119 Cooper et al. also raised concern for
potential dural injury resulting from use of powered instruments and subsequent
inhibition of calvarial healing.93 To test this hypothesis, different surgical techniques
were applied, including standard trephine with preservation of the dura versus trephine
with disruption of dura.

In a third group, defects were created using a trephine to drill

through the ectocortex and variable thickness of the endocortex, using a periosteal
elevator to complete the defect through the endocortex. Greater bone healing resulted in
the group treated using the modified trephine with periosteal elevator for defect creation.
Since the defect margin was created irregularly using the periosteal elevator, bone healing
may have been overestimated within this group.
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Dermal biopsy punches were used to create calvarial defects within this study.
Circular defects were created with sharp, regular margins. Since these instruments were
hand driven, surgical technique minimized the potential for thermal osteonecrosis.
Avoidance of heat generation ensured preservation of the small dural arterioles in close
proximity, which supplied both vascularized bone grafts and native parietal bone.
4.2 PATTERNS OF CALVARIAL DEFECT HEALING

Heine (1926) observed that calvarial defect healing progressed from both the
native bone edges as well as bone islands originating from the dura mater.120 Dural
osteogenesis is the dominant mechanism of calvarial healing; bone formation decreases
significantly in its absence.121' 122 Bone healing progressed through islands of new bone
formation within the majority of Defect and Treatment sides in Control and EXP2
groups. Within these groups, the Treatment side was partially filled with native parietal
bone or vascularized bone graft. In contrast, defect healing on the Treatment side in
EXP1 occurred primarily from bone margins in the presence of non-vascularized bone
grafts.
The majority of previous studies noted progression of calvarial healing from
defect margins. Gurevitch et al. (2003) for example, observed healing from bone margins
within calvarial defects filled with demineralized bone matrix.

When fibrin glue was

added, containing fibrinogen and thrombin which are involved in the coagulation
cascade, healing occurred as islands of new bone formation. Differences in healing
patterns within previous studies may be attributed to the presence of inert scaffolds, as
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seen in EXP1 within this study.20,67’69,72"73, 123-125 Sampling error of histologic
preparations may be a confounding variable however in some cases. Histologic
examinations are limited to two-dimensional slices, which may fail to identify small
islands of bone formation. Bone islands were identified within this study using microCT, which provided high resolution non-destructive imaging of three-dimensional bone
architecture.
Bone graft vascularity may alter basic mechanisms of calvarial healing. Findings
from this study suggest that a feedback loop may exist during calvarial healing, which
determines whether appositional, dural, or pericranial osteogenesis is the dominant
mechanism. In the presence of non-vascularized bone grafts, bone healing was limited to
defect margins and appeared to inhibit dural osteogenesis. Non-vascularized bone grafts
may shift the balance towards greater osteoclastic versus osteoblastic activity.
Remodelling and revascularization of non-vascularized bone grafts may become the
dominant process, therefore making dural osteogenesis less efficient for repair of residual
calvarial defects. Marginal healing appeared to progress through appositional bone
growth.
Dural osteogenesis involves complex interactions between several osteogenic
growth factors, including transforming growth factor beta-1, basic fibroblast growth
factor, collagen type Ial, osteocalcin, and alkaline phosphatase.

Select growth factors

secreted by the dura may stimulate endothelial cells in vascularized bone grafts and
native parietal bone, which may promote further angiogenesis and bone healing. There
may be a synergistic effect on dural osteogenesis from growth factors secreted by the
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dura and vascularized bone grafts. The presence of vascularized bone graft may also
increase bone metabolism, promoting osteoblastic activity and bone formation within
calvarial defects. Remodelling of non-vascularized bone grafts may inhibit the release of
osteogenic growth factors from the dura.
Bone graft vascularity may alter mechanical forces acting on the dura and
subsequently affect dural osteogenesis. Mechanical strain has been shown to increase
dural osteogenesis through increased osteoblast differentiation.127 Osteocyte death occurs
within non-vascularized bone grafts, which may decrease graft volume on a microscopic
level and decrease mechanical forces acting locally.

10 8

Interestingly, calvarial healing was not statistically different between the Defect
versus Treatment (Bone Graft) sides within EXP1. No differences in BMC were seen
over time within defects partially closed with non-vascularized bone graft versus those
left empty, leaving an initial bone defect of larger surface area. Non-vascularized bone
graft crescents demonstrated greater BMC over time as compared to empty crescents and
may provide a scaffold for calvarial healing. Although non-vascularized bone grafts
resulted in greater healing at defect margins, they did not promote bone production within
central defects.
4.3 RAT SKULL GROWTH AND IMPACT ON CALVARIAL DEFECT MODEL

In agreement with previous findings, rat skull growth continued through
adulthood within this study.86,129' 130 Rats were approximately ten weeks at the time of
surgery and had therefore reached sexual maturity.130 Although the growth rate
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decreased over time, skull growth continued through study completion.

1 ?Q

On average,

neurocranium length increased approximately 10% up to 22 weeks of age compared to a
slightly lower increase (7.5%) increase in width. This differential growth has previously
been cited in the literature.129
The effect of skull growth on calvarial defect dimensions over time has not been
determined. It is unknown, for example, whether a 4mm calvarial defect will increase in
size proportionately to skull growth or if it remains stable through growth. Maximum
length and width of calvarial defects were recorded from MIPs at different time points.
When bone healing was complete or near complete, it was not possible to measure
calvarial defect dimensions using this technique. When less bone healing occurred,
measurements of calvarial defects were recorded either based on maximum residual
defect dimensions or between interfaces of native parietal and new bone formation at
defect margins. Measurements of length and width confirmed that calvarial defects
increased in size proportionate to neurocranium growth. Previous studies have not
accounted for ongoing skull growth through adulthood when using the rat calvarial defect
model. New bone formation at defect margins may therefore have been underestimated.
Within this study, BMC was underestimated up to 30% at 12 weeks post-operatively
when not accounting for skull growth.
4.4 CALVARIAL BONE GRAFT HEALING AND VASCULARITY

Fukuta et al. (1992) found greater resorption of non-vascularized versus
vascularized bone grafts when placed in the temporal fossa as onlay grafts.107
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Vascularized bone grafts were supplied by pericranial vessels in contrast to the dural
arteriolar supply to vascularized grafts within this study. Volume was measured using
the water displacement method, which showed approximately 50% resorption of nonvascularized bone grafts. Fukuta et al. (1992) found normal bone architecture on
histological examination of vascularized bone grafts at 12 weeks in comparison to fibrous
tissue ingrowth within non-vascularized bone grafts.107 Cutting and McCarthy (1983)
similarly found less resorption of vascularized versus non-vascularized onlay bone grafts
in composite myoosseous flaps assessed by bone sample weights.

131

Antonyshyn et al. (1986) compared non-vascularized versus vascularized inlay
bone grafts within calvarial defects.132 Vascularized bone grafts were supplied through
attachments to the temporalis muscle and pericranium. Vascularity was confirmed using
technetium scintigraphy (or bone scans) to see uptake of radionuclide. Histological
examination at 42 days post-operatively showed osteocytes and cellular marrow in
vascularized bone grafts in contrast to acellular marrow and empty lacunae in nonvascularized bone grafts.
Using micro-CT, our study permitted precise quantification of bone mineral
content within bone grafts over time. No significant resorption occurred for either nonvascularized or vascularized bone grafts, which were placed as inlay grafts within parietal
defects. Vascularized bone grafts demonstrated greater BMC than non-vascularized
grafts at two weeks post-operatively, which may suggest that vascularity plays a role in
early bone graft healing. Previous studies have shown acellular marrow and lack of
osteocytes in non-vascularized bone grafts in early bone graft healing.
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Our results did

not show any differences in BMC between non-vascularized and vascularized bone grafts
as healing progressed through 6 and 12 weeks post-operatively. Non-vascularized bone
grafts, although acellular, may provide a scaffold for early bone healing and ingrowth of
blood vessels.
Many factors influence bone graft survival, including mechanical stress, skeletal
fixation, and embryological origin.2 Bone graft stabilization and mechanical forces have
been found to increase bone deposition, while limited stress may lead to bone resorption.2
Bone graft survival is also affected by embryological origin. Greater resorption has been
shown for endochondral versus membranous bone grafts.133'136 Despite absence of load
bearing in the parietal region, bone grafts did not undergo significant resorption over
time. No instances of bone graft migration were seen.
4.5 REGIONAL DIFFERENCES IN CALVARIAL HEALING

Within EXP3 group, higher BMC was seen at weeks 6 and 12 for vascularized
\

bone grafts created posteriorly versus anteriorly in the parietal bone. In addition, empty
crescents created posteriorly demonstrated higher BMC at weeks 6 and 12 than those
created anteriorly. Findings suggest increased osteogenic potential of the posterior
parietal bone, which may be related to regional differences in skull vascularity. An
alternative possibility is that underlying brain growth may be greater posteriorly, which
may increase mechanical strain on the dura and further promote dural osteogenesis.
Proximity to muscle insertions and cranial sutures may play an additional role. For
example, the lambdoid sutures or posterior aspect of the sagittal suture may demonstrate
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increased osteogenic potential. It is also possible that contractile forces generated by the
temporalis muscles may be greater in the posterior fibres.
4.6 EFFECTS OF RADIATION ON CALVARIAL HEALING

Radiation exposure from serial micro-CT scans may affect calvarial healing.
Cumulative radiation dose is dependent on the scanning frequency and image
resolution.137 Therapeutic irradiation levels have been associated with inhibition of
osteoblast differentiation, decreased bone marrow cells, and antiangiogenesis138' 142
Deleterious effects of lower radiation doses on bone production remain controversial,
however a threshold level of 40cGy has been theorized.137,143 Timing of irradiation may
also play a role. Arnold et al. (1998) found that high dose radiation at four days postoperatively or later did not affect bone healing, once granulation tissue has been
established within femur defects.
Effects of radiation on calvarial defect healing within this study remain unknown.
The imaging protocol at our centre has been optimized at approximately 30cGy per
acquisition to minimize radiation exposure, while maintaining adequate resolution to
study bone microarchitecture.100 All rats underwent the same number of micro-CT scans
using the same protocol at standardized time points. Subject to an equivalent cumulative
dose, animals within this study therefore served as their own controls. Both vascularized
and non-vascularized bone grafts may potentially be affected by high dose irradiation,
due to direct damage to microvessels and disruption of angiogenesis.140,144
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4.7 WEAKNESSES
This is one of the first studies to account for skull growth on calvarial defect
healing and to measure the same ROI over time by co-registering scans. Limitations exist
however when applying rigid body registration to growing skulls over time. There are no
stationary landmarks within the rat skull as it continues to grow through adulthood. Rat
skulls were co-registered based on anterior versus posterior cranial suture landmarks in
attempt to account for these limitations. Correlation was shown between micro-CT scans
registered according to different sets of landmarks. In addition, ROIs in co-registered
scans were multiplied by the average increase in neurocranium length and width to
account for skull growth. Cranial vault growth was measured from two-dimensional
images using an established method.86 Volumetric changes in the cranial fossae were not
assessed, which may demonstrate differential growth patterns.
Although vascularized bone grafting is associated with enhanced dural
osteogenesis, the mechanism of action was not proven by this study design. Surgical
technique for harvesting non-vascularized bone grafts may have contributed to the
inhibition of dural osteogenesis. Since vascularized bone grafts were supplied by
perforating dural arterioles, they were not elevated from the dura. In contrast, nonvascularized bone grafts were completely separated from the dura and replaced
orthotopically. Malleable retractors were used to prevent dural laceration from the
dermal biopsy punch, however micro-injury to the dura may have occurred during
elevation of the non-vascularized bone grafts as perforating dural arterioles were divided.
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Biomolecular studies will be performed to measure markers of osteoclastic and
osteoblastic activity to further understand mechanisms regulating dural osteogenesis.
4.8 FUTURE WORK

Contrast-enhanced micro-CT scans will be performed in order to further delineate
the blood supply of the cranial vault. Microfil® is a radioopaque lead-based polymer that
may be injected as a terminal procedure to outline the vascular architecture (Flow Tech
Inc., Carver, MA, USA). Animals will be sacrificed at staged time points (weeks 0,2, 6,
and 12) in order to permit further comparisons with non-enhanced scans. Patterns and
density of blood vessels will be studied within calvarial defects partially closed with nonvascularized versus vascularized bone grafts to better understand the pathophysiology of
calvarial defect healing. Contrast-enhanced scans performed immediately postoperatively will confirm that the blood supply from dural arterioles is maintained to
vascularized bone grafts, as shown intra-operatively within this study.
The effects of bone graft vascularity on regulating dural osteogenesis will be
further evaluated through histological examinations and biomolecular studies, including
growth factor immunoassays to measure osteoblastic versus osteoclastic activity. Single
photon emission computed tomography (SPECT) scans will also be performed.
Comparisons of SPECT activity in vivo between groups may lead to greater
understanding of bone metabolism and calvarial healing in relation to bone graft
vascularity.
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CHAPTER 5.0 - CONCLUSIONS

Bilateral defects were created to study the effects of non-vascularized versus
vascularized bone grafting on calvarial healing in a rodent model. Our surgical technique
reliably created vascularized bone grafts based on the blood supply from perforating
dural arterioles with minimal donor site morbidity. Calvarial defects were created using a
dermal biopsy punch, which minimizes potential for thermal injury to bone. Bone grafts
were successfully performed without rigid fixation, which did not result in significant
resorption or graft migration over time. Micro-CT provided high resolution, quantitative
evaluation of bone healing in vivo. The bilateral model permitted statistical analysis
comparing Defect and Treatment sides within and across groups over time.
Calvarial healing is a complex process involving a balance between dural
osteogenesis, pericranial, and appositional growth. Findings from this study suggest that
regulation of dural osteogenesis may be affected by bone graft vascularity. Bone
formation was greater within native parietal bone and vascularized bone grafts at later
stages with dural regeneration appearing primarily responsible for closing calvarial
defects. Non-vascularized bone graft healing was limited to defect margins and may
therefore inhibit dural osteogenesis.
No differences existed in mineralization of vascularized versus non-vascularized
calvarial bone grafts over time. Correlation was found for measurements recorded from
anteriorly- versus posteriorly-based rigid body registrations. In addition, bone mineral
content correlated with bone mineral density and fractional area over time. The cranial
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vault may demonstrate regional differences in healing potential, which may relate to
underlying brain growth, proximity to cranial sutures and muscle insertions, or anatomic
variations in vascularity.
Greater understanding of vascular mechanisms underlying calvarial healing, as
presented in this thesis research, will have implications for cranial vault reconstruction in
future clinical settings.
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1 .7608
1 .6496

2 .2 3 7 3
1.8213

5 .1847
4 .4 9 6 9

5
16

0
0

EXP1
EXP1

1 .5 8 1 4
1.3641

1.0764
1 .2 7 3 4

1.7183
1.8413

4 .3 9 8 2
4 .5 3 1 4

17
20

0
0

EXP1
EXP1

1.2593
1.1 8 4

1.7429
1 .1054

1.3694
0 .8964

4 .2 6 4 3
4 .1 2 8 7

32
33

0
0

EXP1
EXP1

1.6723
1.3999

1.358
1 .5077

0.9618
1.8973

3 .8 5 9 7
3 .3909

37
39

0
0

EXP1
EXP1

1 .6482
1.3681

1.5398
0 .6 6 1 9

4 .4 0 4 9
4 .3 2 6 9

6
7

0
0

EXP2
EXP2

1 .6358
1.9001

1.885
2 .1655

4 .6 5 8
4 .9196

8
14

0
0

EXP2
EXP2

1.9483
1.3718
2 .1 0 1 4
1-6879
1.2 8 7
1.632

1.3557
1.6873

1.2917
1.9006

4 .9 1 0 1
3.8532

15
24

0
0

1.7507
1.1927

1.4145
0 .7 8 1 3

1.9001
0.608

5 .1 8 9 7
4 .0 5 9 9

31
35

0
0

EXP2
EXP2
EXP2
EXP2

1.7238
1 .4274

1.1323
1.1216

2.1426
1.5494

4 .1 3 1
5 .7557

36
38

0
0

EXP2
EXP2

0 .9 2 3 8
1.1709

0.808
1.5771

4 .6 0 6 6
4 .7 3 0 1

11
12
21
28

0
0
0
0

EXP3 ANT
EXP3 ANT

1 .0899
1.1622

EXP3 ANT
EXP3 ANT

1 .1018
0 .9 5 5
1.5054
0 .7 2 2

1.2452
1 .2896
1.5729
1.1098
1.5414

34

0

EXP3ANT

1 .4419

10
13

0
0

EXP3 POST
EXP3 POST

1.1765
1.0301

25
26

0
0

EXP3 POST
EXP3 POST

1 .8578
0 .9 9 9 5

1.4902
1.397
1.1385
1.9014
1.7337

30

0

EXP3 POST

1.2195

1.3604

1.4823

1-5232
1 .2 1 3 8

T re a tm e n t A n t C re s c e n t

T re a tm e n t P o s t C r e s c e n t

4 .6 5 1 7
5 .5556

4 .3 0 5 3
4 .5383

4 .2 9 9 1
4 .3 0 2 1

5 .3 9 4 9
4 .5 0 2 7

1 .3401

1.2671
1.7062
1.7264
1.6288
1 2744

4 .1 7 2 7

4 .8 2 7 6

1.199
1.0127

1.5735
1.5254

4 .9252
4 .9 7 9 5

4 .9 7 0 7
5.512

1 .699
1 .1218

2.7274
1.3002

4 .7 5 3 5
4 .2 7 6 6

5 .7366
4 .3 1 4 8

1 .4297

1.3243

4 .3 6 5 2

5.3 4 7

1 .3798

Table 3.3.0. BM C M easurem ents accounting for Skull Growth per group at w eek 0. BM C expressed in m g.

R at

Wn K

G ro u p

l

2

CONTROL

9
18
19
22
40
3
4
5
16
17

2
2
2
2
2
2
2
2
2
2
2
2
2

CONTROL
CONTROL
CONTROL
CONTROL
CONTROL
EXP1
EXP1
EXP1
EXP1
EXP1
EXP I
EXP1
EXP1

31
35
36
38
11
12
21

2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

EXP1
EXP1
EXP2
EXP2
EXP2
EXP2
EXP2
EXP2
EXP2
EXP2
EXP2
EXP2
EXP3 ANT
EXP3 ANT
EXP3 ANT

28
34
10
13
25
26
30

2
2
2
2
2
2
2

EXP3 ANT
EXP3 ANT
EXP3 POST
EXP3 POST
EXP3 POST
EXP3 POST
EXP3 POST

20
32
33
37
39
6
7
8
14
15
24

D e fe c t S id e
2.7847

D e fe c t A n t C re s c e n t

D e fe c t P o s t C r e s c e n t

T re a tm e n t S id e

1.7787

3.419
4 .6 6 6

2.9435
3.8402

2 .8159
4 .4 1 3 3
4 .6 3 1 3

2.7368
1.8719
3.2111
3.0507

2.4838
2.7838
3.0998
1.9549
2.225
3.169
3.3022
3.8677
3.6064

4 .9 4 3 3
1.4995
2.1801
2 .8 7 4 9
4 .4 8 1 9
2 .4866
4 .8 4 2 7
3.2719
3.4445

2.8225
2.3717

3.6335
3.2486
2 .2 7 2 8
2.4741
3.4973

3.2986
2.8752
3.4209
4.4172
3.8497
4.3157
2.8528
3.6128
2.9135
3.5342
2 .7 6 7 6
2.7486
3.4476
3.2468
3.886
4.3104

3.489
2.5097
3.6525
2.5302
2.5719
4.0051
2.1906
2.4024
3.1106
2.796
2.894

2.0962
3.0728
3.3187
1.69
1.2697
3.3496
2.5157
2 .0079
2.4052
2.1174
2 .2699
1.9333
5.2101

1.4686
1.6036
2.2091
3.0899
2.286
2 .1 2 3 6
2.5053
2.4672
2 .9648
5.894

3.6231
2.286
1.5412
2.8623
4.2971
2 .5664
1.6878
4.0822
2.8131
3 .2737
5 .4086

T re a tm e n t A n t C r e s c e n t

T re a tm e n t P o s t C r e s c e n t

5.2915
6.306
5.365
6.639
5.9674
5.9708
6.4823
4.7457
5.7484
5.6762
6.7082
6.238
6 .1407

5.3716
3.0698
4 .1 7 7 5
4 .1 8 3 8
4 .4 6 5 7
3.9733
2.0998
2.9261
3 .9227
2 .6 1 2 8
2 .9 4 2 7
2 .5 0 7 4

5.4642
6 .7709
4.9869

3 .8006
2 .5 4 4 7
2 .8 7 4 7
3.0911
3.8401
1.7462
5 .6078

7.3825
6.6 2 8
5.5635
6.3938
4.2 8 8
4 .3966
7.002

6.5146
6.5606

Table 3.3.1. BM C M easurements accounting for Skull Growth per group at w eek 2. BM C expressed in m g.

7.7769
6.6669
7.8033
5.7409
6.4475
6 .1282
6.8621
5.7389
6.6958
5.6933
6.0493
7.3964
6.511
6.1505
11.3403

R at
l
9
18
19
22
40
3
4
5
16
17
20
32
33
37
39

WMk
6

6

6

7
8
14
15
24
31
35
36
38
11
12
21
28
34
10
13
25
26
30

6

6

6
6
6

6
6
6

6
6
6
6
6

6
6
6

6

6
6

6
6
6
6
6
6

6
6
6
6
6

6
6
6

6

D e fe c t S id e
G ro u p
CONTROL
3.9589
CONTROL
5.9446
CONTROL
7.5493
CONTROL
3.4301
CONTROL
6.6116
CONTROL
3.7906
EXP1
4.8452
EXP1
6.1571
EXP1
5.1136
EXP1
5.6134
EXP1
8.0192
EXP1
8.3619
EXP1
6.4832
EXP1
6.2444
EXP1
7 .0139
EXP1
6.5175
EXP2
4.763
4.2007
EXP2
EXP2
4 .5 1 1 6
EXP2
5.4079
EXP2
5.9865
5.4719
EXP2
EXP2
7.0561
EXP2
4.0956
EXP2
5.3171
7.059
EXP2
EXP3 ANT
2.5923
EXP3 ANT
3.1091
EXP3 ANT
7.793
EXP3 ANT
3.0571
EXP3 ANT
3.7322
EXP3 POST
4.585
EXP3 POST
4 .1 9 1 6
5.4111
EXP3 POST
5.4057
EXP3 POST
EXP3 POST
5.6021

D e fe c t A n t C re s c e n t

D e fe c t P o s t C r e s c e n t

1.682
3.0796
4.7733
3.9288
3.8208
2.9897
4 .2259
5.0438
4 .1686
S.9776

2.7399
4.6 6 6
6.5755
6.4249
6.7073
5.674
2.2722
3.2563
4.7818
4 .2192
5.8762
7.5
5.4787
4 .7739
8.228
5.5836
4 .5191
4 .6385
4.825
7.2358
4.7787
3.6022
4.7274
3.3902
6.2796
6.295
2.7706
2.9966
6.7808
5.813
4.2505
4 .2959
6.9778
5.837
6.1119
6.1108

T re a tm e n t S id e
4.1805
68004
8.1111
7.8708
7.025
5.4432
5.7105
6 .9925
3.5844
7.5807
4.5121
8.014
5.3306
5 .1554
5 .5998
4 .8 8 4 5
5.2066
8 .3347
6 .3987
6 .5177
8.0041
7.6972
7.8869
4 .4276
5.774
5.5835
3.8597
7.0237
3.9012
6.1998
5.454
6.2408
5.5861
7.5214
3.5894
6.4604

T re a tm e n t A nt C re s c e n t

T re a tm e n t P o s t C re s c e n t

6.4744
9.3335
7.1404
8.155
10.7822
8.3539
8.3105
7.6741
5.4283
8.8034

7.907
8.7369
7.5248
8.346
8.3848
10.4547
8.9102
5.4746
10.1771
8.9648
7.5378
8.5775
9.8812
7.5466
8.8658
11.1338
8.7111
9.9538
9.0142
8.6536
8.8661
9.363
9.7179
8.0969
8.5654
9.1189
10.3689
9.8642
9.5234
11.7269

Table 3.3.2. BM C M easurements accounting for Skull Growth per group at w eek 6. BM C expressed in mg,

R at
l
9
18
19
22
40
3
4
5
16
17
20
32
33
37
39
6
7
8
14
15
24
31
35
36
38
11
12
21
28
34
10
13
25
26
30

W tt k

G ro u p

12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12

CONTROL
CONTROL
CONTROL
CONTROL
CONTROL
CONTROL
EXP1
EXP1
EXP1
EXP1
EXP1
EXP1
EXP1
EXP1
EXP1
EXP1
EXP2
EXP2
EXP 2
EXP2
EXP2
EXP2
EXP2
EXP2
EXP2
EXP2
EXP3 ANT
EXP3 ANT
EXP3 ANT
EXP3 ANT
EXP3 ANT
EXP3 POST
EXP3 POST
EXP3 POST
EXP3 POST
EXP3 POST

D afact S id a
4.3918
8.6257
8.934
3.577
7.4241
4.4887
5.1464
7.8587
8.2985
8.3141
8.6826
9.9737
8.9314
7.9258
8.2707
8.4989
6.3915
5.2024
6.3158
7.8031
6.8369
8.4825
8.7808
4.6526
6.3067
9.3582
4.4192
3.0517
11.2155
3.5428
4.7218
5.7895
6.0221
6.6508
6.014
5.8475

D afact A nt C ra sc a n t

2.7057
3.141
5.1508
6.1237
4.6636
3.4814
7.169
5.5064
5.2183
7.4883

D afact P o s t C ra sc a n t
3.057
7.5751
8.5941
7.1761
8.3419
7.1727
2.4724
4.815
5.3051
6.6242
8.7701
8.7541
7.6755
6.5702
9.8911
8.3075
6.2934
5.3489
6.6441
8.9075
5.6612
5.9666
6.4361
5.386
6.7845
9.0961
4.5602
3.1427
7.7754
7.1444
5.0998
5.3522
9.1282
7.6825
8.5803
8.2833

T ra a tm a n t S id a
4.9904
9.5299
9.549
8.7886
9.5928
6.6489
8.1917
94134
5.9437
10.1505
5.7093
89665
7.2254
6.0728
6.4084
8.4611
7.5061
10.0098
7.6593
9.3G69
8.3886
10.4614
10.5801
5.6029
6.7109
7.6241
5.6505
6.0291
4.2497
6.6789
6.4449
6.9735
8.4063
9.3633
3.9334
8.0068

T ra a tm a n t A nt C ra sc a n t

T ra a tm a n t P o s t C ra s c a n t

8.3477
11.1598
8.7163
10.3617
11.5622
10.3914
11.0249
11.1071
5.99
9.3365

8.6114
9.2301
9.5092
11.651
9.9415
12.4508
11.088
8.3762
11.9982
11.7843
11.7749
9.2169
12.3767
10.6544
9.1383
12.9495
10.1422
11.3416
9.3256
10.7044
10.4684
11.1201
11.7275
10.8682
10.1716
11.9489
13.9271
12.4144
10.5305
12.5256

Table 3.3.3. BM C M easurements accounting for Skull Growth per group at w eek 12. BM C expressed in mg.

